Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Additionally, Arcturus’s robust pipeline, including ARCT-154 for COVID-19, ARCT-810 for OTC deficiency, and ARCT-032 for cystic fibrosis, demonstrates promising risk-adjusted per share values.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

The severe acute respiratory syndrome coronavirus 2 just keeps doing what it does oh-so-well: it just keeps mutating and mutating and mutating, resulting in more and more variants. Leading the ...

Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...